Survival in metastatic breast cancer has increased in recent years, but 5-year survival rates remain below 50% and the mechanisms of spreading remain to be elucidated. An emerging strategy to inhibit the progression of tumors consists of acting on tumor-associated macrophages to displace them from an M2-like phenotype to an M1-like phenotype.